Although the cause of multiple myeloma is not known, research shows that genetic changes in the DNA of a single plasma cell ...

Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a ...

They may also assess for any bone fractures or breaks since multiple myeloma cancer cells can weaken bones, increasing the risk of bone fractures. Multiple myeloma affects the health of several ...

The FDA has approved two new biosimilars of denosumab-dssb to treat osteoporosis, increase bone mass, prevent ...

Ospomyv, a biosimilar to Prolia, treats osteoporosis in postmenopausal women at high risk for fracture ... in patients with multiple myeloma and in patients with bone metastases from solid ...

Bone disease is a hallmark of multiple myeloma (MM), associated with bone pain, pathological fractures requiring surgery and/or radiation to bone, spinal cord compression and hypercalcemia.

Inside most of your bones is a soft, spongy tissue called bone marrow ... causing pain and fractures. Treatments for multiple myeloma target the cancer cells as well as the symptoms.

Multiple myeloma symptoms include bone pain or fractures, backache, frequent infections, weight loss, fatigue, and other conditions. We diagnose multiple myeloma by doing blood, urine, bone marrow, ...

The FDA has approved the BLA for Ospomyv™ and Xbryk™, biosimilars to Prolia (denosumab) and Xgeva (denosumab), respectively.

Wānaka resident and multiple myeloma blood cancer patient Emma Holden, 36, will soon travel to Shanghai, China for ...